BioCentury | Jan 11, 2021
Deals

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

More than a decade after Kymab was first backed by the Wellcome Trust to derive drug candidates from an engineered mouse model, the company has accepted a $1.1 billion takeout offer from Sanofi that closely...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Dec 4, 2020
Product Development

AZ’s opportunity to expand the severe asthma market with tezepelumab

Phase III data from AstraZeneca and Amgen’s tezepelumab suggests the mAb could substantially expand the use of biologics in severe asthma beyond the subset of patients addressed by marketed therapies....
BioCentury | Nov 30, 2020
Finance

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

Kinaset is launching with a $40 million series A led by  5AM Ventures and Atlas Venture with participation from Gimv to develop an inhaled immunomodulator that will compete with biologics in severe...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

Roche’s mAb depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London scientists reported in Nature Cancer that the anti-CD25 mAb RG6292, which is in a Phase I trial in advanced...
BioCentury | Oct 22, 2020
Product Development

Data Byte: AbbVie’s oral JAK takes the lead in coming competition for Dupixent in atopic dermatitis

Phase III data for coming entrants to the atopic dermatitis market show Rinvoq upadacitinib from AbbVie Inc. (NYSE:ABBV) has the edge in efficacy, compared with three other Phase III programs and the marketed therapy Dupixent...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Blocking glucocorticoid signaling to increase checkpoint inhibitor sensitivity

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Inhibiting the glucocorticoid receptor could treat melanoma and colorectal cancer and enhance sensitivity to checkpoint blockade. In...
BioCentury | Aug 29, 2020
Product Development

Next-wave Th1 cytokine cancer therapies aim for more precise targeting

A growing list of cytokine therapies have been designed to boost cytotoxic immune responses against cancer while sidestepping the limitations of past candidates by controlling where the molecules do and...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s $115 million series C round.  Additional new investors Lilly...
Items per page:
1 - 10 of 378